Biotech and emerging pharmaceutical stocks continue to be hot, but short sellers shied away from many of them in late February. Those bucking that trend include BioMarin Pharmaceutical and Medivation.
After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical stocks in early February. The largest upswings happened to BioMarin Pharmaceutical and…
24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers shied away from these stocks in late January.
Before the markets opened Wednesday morning, drug giant Merck & Co. reported fourth-quarter and full-year 2013 results that failed to dazzle. But shares traded higher in the premarket session.
Biogen Idec surprised investors Wednesday with weaker-than-expected guidance for 2014 earnings. Amgen beat estimates late Tuesday. Celgene and Gilead Sciences report earnings on Thursday.
Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across the board.…
ThinkstockAmgen Inc. (NASDAQ: AMGN) is the second largest biotech player, and now we have seen its fourth-quarter earnings report. Earnings came in up 30% at $1.82 per share, and revenue was up…
Jon C. Ogg Here are some of the top biotech names to buy at Cowen. They presented such an extensive list that we focused on the quality large cap names and the stocks with the…
The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.
ThinkstockInvestors love dividends, particularly safe and dependable dividends that rise through time. The S&P 500 Index currently has the most companies paying dividends in nearly two decades. The year 2013 has seen…
ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies locally, but a new report from IMS Health shows that the total…
ThinkstockMany Wall Street analysts and strategists are forecasting a rise in corporate earnings for the rest of the year and throughout 2014. That is music to the ears of stock investors. Rising…
ThinkstockThe UBS proprietary institutional flow data indicates that hedge funds are increasing exposure to financials and decreasing exposure to health care. Given that health care has outperformed significantly year to date, hedge…
Jon OggThe S&P 500 Index is hitting all-time highs and we are now deep into earnings season. This week will mark the second week of the earnings floodgates being open. 24/7 Wall…
ThinkstockThe world of biotechnology investing is a constantly evolving and changing one. While disease for the most part does not change all that much, the manner in which it can be treated…
